Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials-Reference-Cited by-同舟云学术

Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials

Published:2023-07-04 Issue:1 Volume:101 Page:38-45
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Ferreira Pamela C.L.¹,Ferrari-Souza João Pedro¹^ORCID,Tissot Cécile¹^ORCID,Bellaver Bruna¹^ORCID,Leffa Douglas T.¹^ORCID,Lussier Firoza¹,Povala Guilherme¹^ORCID,Therriault Joseph¹,Benedet Andréa L.¹,Ashton Nicholas J.¹^ORCID,Cohen Ann D.¹,Lopez Oscar L.¹,Tudorascu Dana L.¹,Klunk William E.¹,Soucy Jean-Paul¹,Gauthier Serge¹,Villemagne Victor¹,Zetterberg Henrik¹^ORCID,Blennow Kaj¹^ORCID,Rosa-Neto Pedro¹^ORCID,Zimmer Eduardo R.¹^ORCID,Karikari Thomas K.¹^ORCID,Pascoal Tharick A.¹,

Affiliation:

1. From the Departments of Psychiatry (P.C.L.F., J.P.F.-S., C.T., B.B., D.T.L., F.L., G.P., A.D.C., D.L.T., W.E.K., V.V., T.K.K., T.A.P.) and Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; Graduate Program in Biological Sciences: Biochemistry (J.P.F.-S., B.B., E.R.Z.), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Translational Neuroimaging Laboratory (C.T., F.L., J.T., J.-P.S., P.R.-N.), McGill University Research Centre for Studies in Aging, Alzheimer's...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000207115

Reference15 articles.

1. Alzheimer's disease drug development pipeline: 2021;Cummings J;Alzheimers Dement (NY),2021

2. NIA-AA research framework: toward a biological definition of Alzheimer's disease;Jack CR;Alzheimers Dement,2018

3. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria;Dubois B;Alzheimers Dement,2016

4. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility

5. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease;Budd Haeberlein S;J Prev Alzheimers Dis,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidomain preventive intervention trials and plasma biomarkers;The Lancet Healthy Longevity;2024-02

2. Vascular risk burden is a key player in the early progression of Alzheimer’s disease;Neurobiology of Aging;2024-01

3. Anti‐amyloid antibody treatments for Alzheimer's disease;European Journal of Neurology;2023-09-11

4. Rumo a uma nova era no diagnóstico e tratamento da doença de Alzheimer;PAJAR - Pan-American Journal of Aging Research;2023-04-28